Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO2TECT correction study of vadadustat versus darbepoetin alfa in anemia due to non-dialysis-dependent chronic kidney disease
MOH_2018-12-05_004828Phase 3Active, not recruiting
- Sponsor
- Akebia Therapeutics
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vadadustat in anemia of renal disease (2 arms), sponsored by Akebia Therapeutics. Primary endpoints: Hemoglobin correction and maintenance efficacy and Safety. Started May 2016; status: active, not recruiting.
02
Drugs
vadadustat
03
Conditions
anemia of renal disease
Beyond the preview
Go deeper on MOH_2018-12-05_004828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-12-05_004828.